Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

 The relation of fibrosis stage with nutritional deficiencies and bioelectrical impedance analysis of body composition in patients with chronic hepatitis C.

Mateos-Muñoz B, Devesa-Medina MJ, Matía-Martín MP, Torrejón MJ, Suárez A, Larrad-Sáinz A, Rey-Díaz-Rubio E, Cárdenas MC, Ortega-Medina L, Ladero JM.

Ann Hepatol. 2016 Jul-Aug;15(4):492-500.

2.

GC Gene Polymorphism and Unbound Serum Retinol-Binding Protein 4 Are Related to the Risk of Insulin Resistance in Patients With Chronic Hepatitis C: A Prospective Cross-Sectional Study.

Mateos-Muñoz B, García-Martín E, Torrejón MJ, Devesa-Medina MJ, Esguevillas G, Cárdenas MC, Fernández C, Carballo M, Agúndez JA, Ladero JM.

Medicine (Baltimore). 2016 Mar;95(10):e3019. doi: 10.1097/MD.0000000000003019.

3.

[Therapeutic update in hepatitis C].

Devesa MJ, Cuenca F, Izquierdo S, Sánchez-Pobre P, Ladero JM, López-Alonso G, Díaz-Rubio M, Rey E.

Rev Esp Quimioter. 2015 Sep;28 Suppl 1:48-51. Review. Spanish.

4.

Matrix metalloproteinase 10 contributes to hepatocarcinogenesis in a novel crosstalk with the stromal derived factor 1/C-X-C chemokine receptor 4 axis.

García-Irigoyen O, Latasa MU, Carotti S, Uriarte I, Elizalde M, Urtasun R, Vespasiani-Gentilucci U, Morini S, Benito P, Ladero JM, Rodriguez JA, Prieto J, Orbe J, Páramo JA, Fernández-Barrena MG, Berasain C, Avila MA.

Hepatology. 2015 Jul;62(1):166-78. doi: 10.1002/hep.27798. Epub 2015 Apr 22.

PMID:
25808184
5.

Influence of vitamin D-related gene polymorphisms (CYP27B and VDR) on the response to interferon/ribavirin therapy in chronic hepatitis C.

García-Martín E, Agúndez JA, Maestro ML, Suárez A, Vidaurreta M, Martínez C, Fernández-Pérez C, Ortega L, Ladero JM.

PLoS One. 2013 Sep 20;8(9):e74764. doi: 10.1371/journal.pone.0074764. eCollection 2013.

6.

Analysis of the Functional Polymorphism in the Cytochrome P450 CYP2C8 Gene rs11572080 with Regard to Colorectal Cancer Risk.

Ladero JM, Agúndez JA, Martínez C, Amo G, Ayuso P, García-Martín E.

Front Genet. 2012 Dec 3;3:278. doi: 10.3389/fgene.2012.00278. eCollection 2012.

7.

Vitamin D deficiency and vitamin D therapy in chronic hepatitis C.

Ladero JM, Torrejón MJ, Sánchez-Pobre P, Suárez A, Cuenca F, de la Orden V, Devesa MJ, Rodrigo M, Estrada V, López-Alonso G, Agúndez JA.

Ann Hepatol. 2013 Mar-Apr;12(2):199-204.

8.

Serum cystatin C: a non-invasive marker of liver fibrosis or of current liver fibrogenesis in chronic hepatitis C? .

Ladero JM, Cárdenas MC, Ortega L, González-Pino A, Cuenca F, Morales C, Lee-Brunner A.

Ann Hepatol. 2012 Sep-Oct;11(5):648-51.

9.

Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function.

Zugazagoitia J, Manzano A, Sastre J, Ladero JM, Puente J, Díaz-Rubio E.

Clin Transl Oncol. 2013 Feb;15(2):146-53. doi: 10.1007/s12094-012-0902-3. Epub 2012 Aug 9.

PMID:
22875650
10.

Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease.

Agúndez JA, García-Martin E, Maestro ML, Cuenca F, Martínez C, Ortega L, Carballo M, Vidaurreta M, Agreda M, Díaz-Zelaya G, Suárez A, Díaz-Rubio M, Ladero JM.

PLoS One. 2012;7(5):e37998. doi: 10.1371/journal.pone.0037998. Epub 2012 May 29.

11.

Polymorphism of the TLR4 gene reduces the risk of hepatitis C virus-induced hepatocellular carcinoma.

Agúndez JA, García-Martín E, Devesa MJ, Carballo M, Martínez C, Lee-Brunner A, Fernández C, Díaz-Rubio M, Ladero JM.

Oncology. 2012;82(1):35-40. doi: 10.1159/000335606. Epub 2012 Jan 26.

PMID:
22286521
12.

Noninvasive evaluation of liver fibrosis in patients with chronic hepatitis C.

Ladero JM.

Hepat Mon. 2011 Sep;11(9):698-700. doi: 10.5812/kowsar.1735143X.738. No abstract available.

13.

Predicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data.

Ladero JM, Martin EG, Fernández C, Carballo M, Devesa MJ, Martínez C, Suárez A, Díaz-Rubio M, Agúndez JA.

J Gastroenterol Hepatol. 2012 Feb;27(2):279-85. doi: 10.1111/j.1440-1746.2011.06834.x.

PMID:
21722179
14.

CYP2W1 variant alleles in Caucasians and association of the CYP2W1 G541A (Ala181Thr) polymorphism with increased colorectal cancer risk.

Gervasini G, de Murillo SG, Ladero JM, Agúndez JA.

Pharmacogenomics. 2010 Jul;11(7):919-25. doi: 10.2217/pgs.10.66.

PMID:
20602611
15.

Predictive baseline criteria of primary therapeutic failure in chronic hepatitis C genotype 1.

Cuenca F, Fernández C, Devesa MJ, López-Alonso G, Mayol J, Suárez A, Ortega L, Díaz-Rubio M, Ladero JM.

Rev Esp Enferm Dig. 2010 Apr;102(4):234-8.

16.

Non-invasive evaluation of the fibrosis stage in chronic hepatitis C: a comparative analysis of nine scoring methods.

Ladero JM, Delkader J, Ortega L, Fernández C, Devesa MJ, López-Alonso G, Mayol J, Cuenca F, Suárez A, Taxonera C, Díaz-Rubio M.

Scand J Gastroenterol. 2010;45(1):51-9. doi: 10.3109/00365520903305544.

PMID:
20030577
17.

Analysis of a non-synonymous single nucleotide polymorphism of the human diamine oxidase gene (ref. SNP ID: rs1049793) in patients with Crohn's disease.

López Palacios N, Agúndez JA, Mendoza JL, García-Martín E, Martínez C, Fuentes Ferrer ME, Ladero JM, Taxonera C, Díaz-Rubio M.

Scand J Gastroenterol. 2009;44(10):1207-12. doi: 10.1080/00365520903171250.

PMID:
19670078
18.

Oscillations in serum ferritin associated with antiviral therapy in chronic hepatitis C.

Ladero JM, López-Alonso G, Devesa MJ, Cuenca F, Ortega L, Agreda M, Suárez A, Ropero P, Díaz-Rubio M.

Rev Esp Enferm Dig. 2009 Jan;101(1):31-40. English, Spanish.

19.

"12 weeks' stopping rule" in the treatment of genotype 1 chronic hepatitis C: two prognostic categories under the same label?

Ladero JM, López-Alonso G, Devesa MJ, Cuenca F, Agreda M, Ortega L, Suárez A, Díaz-Rubio M.

Scand J Gastroenterol. 2008 Aug;43(8):979-83.

PMID:
19086280
20.
21.

Refinement of the basis and impact of common 11q23.1 variation to the risk of developing colorectal cancer.

Pittman AM, Webb E, Carvajal-Carmona L, Howarth K, Di Bernardo MC, Broderick P, Spain S, Walther A, Price A, Sullivan K, Twiss P, Fielding S, Rowan A, Jaeger E, Vijayakrishnan J, Chandler I, Penegar S, Qureshi M, Lubbe S, Domingo E, Kemp Z, Barclay E, Wood W, Martin L, Gorman M, Thomas H, Peto J, Bishop T, Gray R, Maher ER, Lucassen A, Kerr D, Evans GR; CORGI Consortium, van Wezel T, Morreau H, Wijnen JT, Hopper JL, Southey MC, Giles GG, Severi G, Castellví-Bel S, Ruiz-Ponte C, Carracedo A, Castells A; EPICOLON Consortium, Försti A, Hemminki K, Vodicka P, Naccarati A, Lipton L, Ho JW, Cheng KK, Sham PC, Luk J, Agúndez JA, Ladero JM, de la Hoya M, Caldés T, Niittymäki I, Tuupanen S, Karhu A, Aaltonen LA, Cazier JB, Tomlinson IP, Houlston RS.

Hum Mol Genet. 2008 Dec 1;17(23):3720-7. doi: 10.1093/hmg/ddn267. Epub 2008 Aug 27.

PMID:
18753146
22.
23.

[Results of the treatment of chronic hepatitis C genotype 4--a comparative analysis with genotype 1].

López-Alonso G, Agreda M, Devesa MJ, Cuenca F, Suárez A, Ortega L, Díaz-Rubio M, Ladero JM.

Rev Esp Enferm Dig. 2008 Apr;100(4):208-11. Spanish.

24.

A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3.

Tomlinson IP, Webb E, Carvajal-Carmona L, Broderick P, Howarth K, Pittman AM, Spain S, Lubbe S, Walther A, Sullivan K, Jaeger E, Fielding S, Rowan A, Vijayakrishnan J, Domingo E, Chandler I, Kemp Z, Qureshi M, Farrington SM, Tenesa A, Prendergast JG, Barnetson RA, Penegar S, Barclay E, Wood W, Martin L, Gorman M, Thomas H, Peto J, Bishop DT, Gray R, Maher ER, Lucassen A, Kerr D, Evans DG; CORGI Consortium, Schafmayer C, Buch S, Völzke H, Hampe J, Schreiber S, John U, Koessler T, Pharoah P, van Wezel T, Morreau H, Wijnen JT, Hopper JL, Southey MC, Giles GG, Severi G, Castellví-Bel S, Ruiz-Ponte C, Carracedo A, Castells A; EPICOLON Consortium, Försti A, Hemminki K, Vodicka P, Naccarati A, Lipton L, Ho JW, Cheng KK, Sham PC, Luk J, Agúndez JA, Ladero JM, de la Hoya M, Caldés T, Niittymäki I, Tuupanen S, Karhu A, Aaltonen L, Cazier JB, Campbell H, Dunlop MG, Houlston RS.

Nat Genet. 2008 May;40(5):623-30. doi: 10.1038/ng.111. Epub 2008 Mar 30.

PMID:
18372905
25.

Glutathione S-transferase GSTT1 and GSTM1 allozymes: beyond null alleles.

Agúndez JA, Ladero JM.

Pharmacogenomics. 2008 Mar;9(3):359-63. doi: 10.2217/14622416.9.3.359.

PMID:
18303971
26.

Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding.

Blanco G, Martínez C, Ladero JM, Garcia-Martin E, Taxonera C, Gamito FG, Diaz-Rubio M, Agundez JA.

Pharmacogenet Genomics. 2008 Jan;18(1):37-43. doi: 10.1097/FPC.0b013e3282f305a9.

PMID:
18216720
27.

Cytochrome P450 CYP2C9 polymorphism and NSAID-related acute gastrointestinal bleeding.

Agúndez JA, Martínez C, García-Martín E, Ladero JM.

Gastroenterology. 2007 Dec;133(6):2071-2; author reply 2072-3. No abstract available.

PMID:
18054585
28.

[The H63D mutation in the HFE gene is related to the risk of hepatocellular carcinoma].

Ropero P, Briceño O, López-Alonso G, Agúndez JA, González Fernández FA, García-Hoz F, Villegas Martínez A, Díaz-Rubio M, Ladero JM.

Rev Esp Enferm Dig. 2007 Jul;99(7):376-81. Spanish.

29.

Glutathione S-transferases pi 1, alpha 1 and M3 genetic polymorphisms and the risk of hepatocellular carcinoma in humans.

Ladero JM, Martínez C, Fernández JM, Martín F, García-Martín E, Ropero P, Villegas A, Díaz-Rubio M, Agúndez JA.

Pharmacogenomics. 2007 Aug;8(8):895-9.

PMID:
17716224
30.

[Utility of liver biopsy in the etiologic diagnosis of biochemical liver abnormalities of unknown cause].

Salueña I, Ortega L, Devesa MJ, López-Alonso G, Taxonera C, Díaz-Rubio M, Ladero JM.

Gastroenterol Hepatol. 2007 Jun-Jul;30(6):325-30. Spanish.

PMID:
17662214
31.

Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.

Gervasini G, García-Martín E, Ladero JM, Pizarro R, Sastre J, Martínez C, García M, Diaz-Rubio M, Agúndez JA.

BMC Cancer. 2007 Jul 2;7:118.

32.

GSTT1 and GSTM1 null genotypes may facilitate hepatitis C virus infection becoming chronic.

Martínez C, García-Martín E, Ladero JM, Herráez O, Ortega L, Taxonera C, Suárez A, Díaz-Rubio M, Agúndez JA.

J Infect Dis. 2007 May 1;195(9):1320-3. Epub 2007 Mar 15.

PMID:
17397002
33.

[Towards a diagnostic strategy of liver disease].

Ladero JM.

An Med Interna. 2007 Jan;24(1):1-2. Spanish. No abstract available.

PMID:
17373860
34.

Glutathione S-transferases mu 1, theta 1, pi 1, alpha 1 and mu 3 genetic polymorphisms and the risk of colorectal and gastric cancers in humans.

Martínez C, Martín F, Fernández JM, García-Martín E, Sastre J, Díaz-Rubio M, Agúndez JA, Ladero JM.

Pharmacogenomics. 2006 Jul;7(5):711-8.

PMID:
16886896
35.

[Hereditary hyperferritinemia and iron overload: they are not synonymous].

Ladero JM.

Med Clin (Barc). 2006 Jun 10;127(2):53-4. Spanish. No abstract available.

PMID:
16801004
36.

Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals.

García-Martín E, Martínez C, Ladero JM, Agúndez JA.

Mol Diagn Ther. 2006;10(1):29-40. Review.

PMID:
16646575
37.

Severity of ulcerative colitis is associated with a polymorphism at diamine oxidase gene but not at histamine N-methyltransferase gene.

García-Martin E, Mendoza JL, Martínez C, Taxonera C, Urcelay E, Ladero JM, de la Concha EG, Díaz-Rubio M, Agúndez JA.

World J Gastroenterol. 2006 Jan 28;12(4):615-20.

38.

A computer-assisted morphometric quantitative analysis of iron overload in liver biopsies. A comparison with histological and biochemical methods.

Ortega L, Ladero JM, Carreras MP, Alvarez T, Taxonera C, Oliván MP, Sanz-Esponera J, Díaz-Rubio M.

Pathol Res Pract. 2005;201(10):673-7. Epub 2005 Sep 26.

PMID:
16325509
39.

Glutathione S-transferase M1 and T1 genetic polymorphisms are not related to the risk of hepatocellular carcinoma: a study in the Spanish population.

Ladero JM, Martínez C, García-Martín E, Ropero P, Briceño O, Villegas A, Díaz-Rubio M, Agúndez JA.

Eur J Cancer. 2006 Jan;42(1):73-7. Epub 2005 Nov 28.

PMID:
16314088
40.

Polymorphisms in the transforming growth factor-beta gene (TGF-beta) and the risk of advanced alcoholic liver disease.

Oliver J, Agúndez JA, Morales S, Fernández-Arquero M, Fernández-Gutierrez B, de la Concha EG, Díaz-Rubio M, Martín J, Ladero JM.

Liver Int. 2005 Oct;25(5):935-9.

PMID:
16162149
41.

Polymorphisms of the glutathione S-transferases mu-1 (GSTM1) and theta-1 (GSTT1) and the risk of advanced alcoholic liver disease.

Ladero JM, Martínez C, García-Martin E, Fernández-Arquero M, López-Alonso G, de la Concha EG, Díaz-Rubio M, Agúndez JA.

Scand J Gastroenterol. 2005 Mar;40(3):348-53.

PMID:
15932176
42.

The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects.

Martínez C, García-Martín E, Blanco G, Gamito FJ, Ladero JM, Agúndez JA.

Br J Clin Pharmacol. 2005 Jan;59(1):62-9.

43.

Hereditary hyperferritinemia-cataract syndrome. Study of a new family in Spain.

Ladero JM, Balas A, García-Sánchez F, Vicario JL, Díaz-Rubio M.

Rev Esp Enferm Dig. 2004 Jul;96(7):507-9, 510-1. English, Spanish.

44.

[HFE gene mutations, hepatic iron content, and histological severity in hepatitis C virus-induced chronic hepatitis].

Ladero JM, Ropero P, Ortega L, Taxonera C, González FA, López-Alonso G, Briceño O, Rodríguez-Agulló JL, González L, Villegas A, Díaz-Rubio M.

Rev Esp Enferm Dig. 2003 Dec;95(12):829-36. English, Spanish.

45.

Leflunomide-induced acute hepatitis.

Sevilla-Mantilla C, Ortega L, Agúndez JA, Fernández-Gutiérrez B, Ladero JM, Díaz-Rubio M.

Dig Liver Dis. 2004 Jan;36(1):82-4.

PMID:
14971821
46.

Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use.

Martínez C, Blanco G, Ladero JM, García-Martín E, Taxonera C, Gamito FG, Diaz-Rubio M, Agúndez JA.

Br J Pharmacol. 2004 Jan;141(2):205-8. Epub 2004 Jan 5.

47.

Single nucleotide polymorphisms and microsatellite alleles of tumor necrosis factor alpha and interleukin-10 genes and the risk of advanced chronic alcoholic liver disease.

Ladero JM, Fernández-Arquero M, Tudela JI, Agúndez JA, Díaz-Rubio M, Benítez J, de la Concha EG.

Liver. 2002 Jun;22(3):245-51.

PMID:
12100575
48.

N-acetyltransferase 2 single-nucleotide polymorphisms and risk of gastric carcinoma.

Ladero JM, Agúndez JA, Olivera M, Lozano L, Rodríguez-Lescure A, Diaz-Rubio M, Benítez J.

Eur J Clin Pharmacol. 2002 May;58(2):115-8. Epub 2002 Apr 17.

PMID:
12012143
49.

Influence of cytochrome P450 CYP2C9 genotypes in lung cancer risk.

García-Martín E, Martínez C, Ladero JM, Gamito FJ, Rodriguez-Lescure A, Agúndez JA.

Cancer Lett. 2002 Jun 6;180(1):41-6.

PMID:
11911968
50.

N-acetyltransferase 2 polymorphism is not related to the risk of advanced alcoholic liver disease.

Agúndez JA, Ladero JM, Olivera M, Lozano L, Fernández-Arquero M, de laConcha EG, Díaz-Rubio M, Benitez J.

Scand J Gastroenterol. 2002 Jan;37(1):99-103.

PMID:
11858170

Supplemental Content

Loading ...
Support Center